Source: European Medicines Agency (EU) Revision Year: 2023 Publisher: PAION Deutschland GmbH, Heussstraße 25, 52078 Aachen, Germany
Pharmacotherapeutic group: Antibacterials for systemic use, tetracyclines
ATC code: J01AA13
The mechanism of action of eravacycline involves the disruption of bacterial protein synthesis by binding to the 30S ribosomal subunit thus preventing the incorporation of amino acid residues into elongating peptide chains.
The C-7 and C-9 substitutions in eravacycline are not present in any naturally occurring or semisynthetic tetracyclines and the substitution pattern imparts microbiological activities including retention of in vitro potency against Gram-positive and Gram-negative strains expressing tetracycline-specific resistance mechanism(s) (i.e., efflux mediated by tet(A), tet(B), and tet(K); ribosomal protection as encoded by tet(M) and tet(Q)). Eravacycline is not a substrate for the MepA pump in Staphylococcus aureus that has been described as a resistance mechanism for tigecycline. Eravacycline is also not affected by aminoglycoside inactivating or modifying enzymes.
Resistance to eravacycline has been observed in Enterococcus harbouring mutations in rpsJ. There is no target-based cross-resistance between eravacycline and other classes of antibiotics such as quinolones, penicillins, cephalosporins, and carbapenems.
Other bacterial resistance mechanisms that could potentially affect eravacycline are associated with upregulated, non-specific intrinsic multidrug-resistant (MDR) efflux.
Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for eravacycline are:
Table 2. Minimum inhibitory concentration breakpoints of eravacycline for different pathogens:
| Pathogen | MIC breakpoints (µg/mL) | |
|---|---|---|
| Susceptible (S ≤) | Resistant (R >) | |
| Escherichia coli | 0.5 | 0.5 |
| Staphylococcus aureus | 0.25 | 0.25 |
| Enterococcus spp. | 0.125 | 0.125 |
| Viridans Streptococcus spp. | 0.125 | 0.125 |
The area under the plasma concentration-time curve (AUC) divided by the minimum inhibitory concentration (MIC) of eravacycline has been shown to be the best predictor of efficacy in vitro, utilising human steady state exposures in a chemostat and confirmed in vivo in animal models of infection.
Efficacy has been demonstrated in clinical trials against the pathogens listed for cIAI that were susceptible to eravacycline in vitro:
Escherichia coli
Klebsiella pneumoniae
Staphylococcus aureus
Enterococcus faecalis
Enterococcus faecium
Viridans Streptococcus spp.
In vitro data indicate that the following pathogen is not susceptible to eravacycline:
Pseudomonas aeruginosa
The European Medicines Agency has deferred the obligation to submit the results of trials with Xerava in one or more subsets of the paediatric population in cIAI (see section 4.2 for information on paediatric use).
Eravacycline is administered intravenously and therefore has 100% bioavailability.
The mean pharmacokinetic parameters of eravacycline after single and multiple intravenous infusions (60 minutes) of 1 mg/kg administered to healthy adults every 12 hours are presented in Table 3.
Table 3. Mean (%CV) plasma pharmacokinetic parameters of eravacycline after single and multiple intravenous infusions to healthy adults:
| Eravacycline dosing | PK parameters arithmetic mean (%CV) | ||||
|---|---|---|---|---|---|
| Cmax (ng/mL) | tmaxa (h) | AUC0-12b (ng*h/mL) | t1/2 (h) | ||
| 1.0 mg/kg intravenous every 12 hours (n=6) | Day 1 | 2125 (15) | 1.0 (1.0-1.0) | 4305 (14) | 9 (21) |
| Day 10 | 1825 (16) | 1.0 (1.0-1.0) | 6309 (15) | 39 (32) | |
a Mean (range) represented
b AUC of Day 1 = AUC0-12 after the first dose and AUC for Day 10 = steady state AUC0-12
The in vitro binding of eravacycline to human plasma proteins increases with increasing concentrations, with 79%, 86% and 90% (bound) at 0.1, 1 and 10 µg/mL, respectively. The mean (%CV) volume of distribution at steady-state in healthy normal volunteers following 1 mg/kg every 12h is approximately 321 L (6.35), which is greater than total body water.
Unchanged eravacycline is the major medicinal product-related component in human plasma and human urine. Eravacycline is metabolised primarily by CYP3A4- and FMO-mediated oxidation of the pyrrolidine ring to TP-6208, and by chemical epimerisation at C-4 to TP-498. Additional minor metabolites are formed by glucuronidation, oxidation and hydrolysis. TP-6208 and TP-498 are not considered to be pharmacologically active.
Eravacycline is a substrate for the transporters P-gp, OATP1B1 and OATP1B3 but not for BCRP.
Eravacycline is excreted in both urine and faeces. Renal clearance and biliary and direct intestinal excretion account for approximately 35% and 48% of total body clearance after administration of a single intravenous dose of 60 mg 14C-eravacycline, respectively.
The Cmax and AUC of eravacycline in healthy adults increase approximately in proportion to an increase in dose. There is approximately a 45% accumulation following intravenous dosing of 1 mg/kg every 12 hours.
Within the range of eravacycline multiple intravenous doses studied clinically, the pharmacokinetic parameters AUC and Cmax demonstrate linearity, but with increasing doses the increase in both AUC and Cmax are slightly less than dose-proportional.
Eravacycline and its metabolites are not inhibitors of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A4 in vitro. Eravacycline, TP-498 and TP-6208 are not inducers of CYP1A2, CYP2B6 or CYP3A4.
Eravacycline, TP-498 and TP-6208 are not inhibitors of BCRP, BSEP, OATP1B1, OATP1B3, OAT1, OAT3, OCT1, OCT2, MATE1 or MATE2-K transporters. The metabolites TP-498 and TP-6208 are not inhibitors of P-gp in vitro.
The geometric least square mean Cmax for eravacycline was increased by 8.8% for subjects with end stage renal disease (ESRD) versus healthy subjects with 90% CI -19.4, 45.2. The geometric least square mean AUC0-inf for eravacycline was decreased by 4.0% for subjects with ESRD versus healthy subjects with 90% CI-14.0, 12.3.
The geometric mean Cmax for eravacycline was increased by 13.9%, 16.3%, and 19.7% for subjects with mild (Child-Pugh Class A), moderate (Child-Pugh Class B), and severe (Child-Pugh Class C) hepatic impairment versus healthy subjects, respectively. The geometric mean AUC0-inf for eravacycline was increased by 22.9%, 37.9%, and 110.3% for subjects with mild, moderate, and severe hepatic impairment versus healthy subjects, respectively.
In a population pharmacokinetic analysis of eravacycline, no clinically relevant differences in AUC by gender were observed for eravacycline.
In a population pharmacokinetic analysis of eravacycline, no clinically relevant differences in the pharmacokinetics of eravacycline were observed with respect to age.
In a population pharmacokinetic analysis it was shown that eravacycline disposition (clearance and volume) was dependent on body weight. However, the resulting difference in exposure to eravacycline in terms of AUC does not warrant dose adjustments in the weight range studied. No data are available for patients weighing more than 137 kg. The potential influence of severe obesity on eravacycline exposure has not been studied.
In repeated dose toxicity studies in rats, dogs and monkeys, lymphoid depletion/atrophy of lymph nodes, spleen and thymus, decreased erythrocytes, reticulocytes, leukocytes, and platelets (dog and monkey), in association with bone marrow hypocellularity, and adverse gastrointestinal effects (dog and monkey) were observed with eravacycline. These findings were reversible or partially reversible during recovery periods of 3- to 7-weeks.
Bone discolouration (in the absence of histological findings), which was not fully reversible over recovery periods of up to 7-weeks, was observed in rats and monkeys after 13 weeks of dosing.
Intravenous administration of high doses of eravacycline has been associated with cutaneous responses (including hives, scratching, swelling, and/or skin erythema) in rat and dog studies.
In fertility studies in male rats, eravacycline administered at about 5 times the clinical exposure (based on AUC), gave rise to a significantly reduced number of pregnancies. These findings were reversible following a 70-day (10-week) recovery period, equivalent to a spermatogenic cycle in the rat. Findings on the male reproductive organs were also observed in rats in the repeated dose toxicity studies for 14 days or 13 weeks at exposures more than 10- or 5-fold the clinical exposure based on AUC. The observations included degeneration of the seminiferous tubules, oligospermia, and cellular debris in the epididymides, spermatid retention in the seminiferous tubules, increase of spermatid head retention in Sertoli cells, and vacuolation of Sertoli cells and decreased sperm counts. No adverse effects on mating or fertility were observed in female rats.
In embryo-foetal studies, no adverse effects were observed in rats at exposures comparable to clinical exposure or in rabbits at exposures 1.9-fold higher than the clinical exposure (based on AUC) in rats and rabbits respectively. Doses more than 2- or 4-fold higher than the clinical exposure (based on AUC) were associated with maternal toxicity (clinical observations and reduced body weight gain and food consumption), and reduced foetal body weights and delays in skeletal ossification in both species and abortion in the rabbit.
Animal studies indicate that eravacycline crosses the placenta and is found in foetal plasma. Eravacycline (and metabolites) is excreted in the milk of lactating rats.
Eravacycline is not genotoxic. Carcinogenicity studies with eravacycline have not been conducted.
Xerava may have the potential to be very persistent in freshwater sediment.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
